search

Active clinical trials for "Alzheimer Disease"

Results 2891-2900 of 2939

Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's...

Alzheimer's DiseaseGlaucoma

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier studies the investigators could demonstrate that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential mRNA expression and an increased fragmentation of the DNA. Such alterations point out a relationship between cellular stress and apoptotic events. Based on the results of mRNA-expression the investigators also expect alterations on the protein level. This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways. Thus, the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with samples from healthy controls. In addition, they will also be compared with samples from patients with Alzheimer's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as positive controls in this study.

Withdrawn9 enrollment criteria

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers....

Alzheimer Disease

To advance current knowledge on the vascular contributions to dementia

Withdrawn13 enrollment criteria

Biomarkers in Neurodegenerative Diseases

Mild Cognitive Impairment (MCI)Alzheimer Disease (AD)9 more

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

Withdrawn38 enrollment criteria

Protein and microRNA Markers for Early Detection of Alzheimer's Disease

Mild Cognitive Impairment

Blood will be harvested from three groups of people, normal control, patients with mild cognitive impairment (MCI) and patients with Alzheimer's disease (AD), 20 people per group. The blood samples will be used to determine the difference in the expression of microRNAs and proteins. Blood samples will be harvested again at 6-month interval from patients. The combination of the microRNAs and proteins that have different expression patterns between normal control and patients with MCI will be constructed in a kit to detect the difference. This kit will be used in another set of the three groups of people to determine its sensitivity and specificity in detecting patients with MCI.

Withdrawn5 enrollment criteria

Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads

Alzheimer's Disease

This non-intervention qualitative study will use focus groups to assess the feasibility and acceptability of a proposed intervention for a future study. The focus group will discuss a potential biobehavioral family self-management intervention designed to improve sleep in persons with Alzheimer's disease (PAD) and their caregivers (CG).

Withdrawn11 enrollment criteria

TB006 Expanded Access (EA) Compassionate Use

Alzheimer Disease

This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.

Available19 enrollment criteria

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

Alzheimer Disease

This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for participation in an ongoing clinical trial. Eligible participants must have previously completed participation in a clinical trial of TRx0237 conducted by TauRx or have previously taken TRx0237 in a compassionate use program, among other criteria. Patients will be considered where a physician can demonstrate clinical benefit for a patient not meeting these criteria; in these cases, TauRx will consider participation of the patient on a case-by-case basis.

Available17 enrollment criteria

Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural...

Alzheimer Dementia

Diffusion Tensor imaging of white matter degeneration in Alzheimer disease

Unknown status9 enrollment criteria

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

Alzheimer DiseaseEarly Onset12 more

This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.

Unknown status18 enrollment criteria

Gut Microbiota and Alzheimer's Diseases

Alzheimer Disease

The investigator will perform clinical studies to test a hypothesis that participants who have Alzheimer's disease will have different gut/oral microbiota profile as compared to the participants who do not have Alzheimer's disease. The investigators will also check the microbiome of their partners in this study. The investigators plan to perform the studies in 150 participants in Shanghai Tenth's People's Hospital and also in the houses in Shanghai city. Investigators will also measure the beta-amyloid in the feces of the participants. Finally, the investigators will determine cognitive function in these participants.

Unknown status3 enrollment criteria
1...289290291...294

Need Help? Contact our team!


We'll reach out to this number within 24 hrs